Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Casi Pharmaceuticals, Inc. (ENMD) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Casi Pharmaceuticals, Inc.. Table 2 shows the detailed insider transactions. This company's CIK number is 895051.
Total stock buying since 2016: $49,123,827.
Total stock sales since 2016: $0.
Total stock option exercises since 2016: $119,615.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2022 | 371,517 | $1,315,039 | 0 | $0 | 0 | $0 |
| 2021 | 3,880,000 | $7,157,799 | 0 | $0 | 0 | $0 |
| 2020 | 6,462,622 | $12,099,997 | 0 | $0 | 0 | $0 |
| 2019 | 180,000 | $571,200 | 0 | $0 | 15,000 | $26,400 |
| 2018 | 6,172,837 | $19,845,670 | 0 | $0 | 61,978 | $93,215 |
| 2017 | 2,341,925 | $1,359,515 | 0 | $0 | 0 | $0 |
| 2016 | 10,295,457 | $6,774,607 | 0 | $0 | 0 | $0 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2022-09 | 67,794 | $275,159 | 0 | $0 | 0 | $0 |
| 2022-08 | 303,723 | $1,039,880 | 0 | $0 | 0 | $0 |
| 2021-11 | 400,000 | $394,000 | 0 | $0 | 0 | $0 |
| 2021-08 | 480,000 | $613,800 | 0 | $0 | 0 | $0 |
| 2021-03 | 3,000,000 | $6,149,999 | 0 | $0 | 0 | $0 |
| 2020-12 | 6,000 | $15,420 | 0 | $0 | 0 | $0 |
| 2020-11 | 227,471 | $488,238 | 0 | $0 | 0 | $0 |
| 2020-07 | 4,172,579 | $7,927,899 | 0 | $0 | 0 | $0 |
| 2020-05 | 525,197 | $1,060,957 | 0 | $0 | 0 | $0 |
| 2020-03 | 1,531,375 | $2,607,483 | 0 | $0 | 0 | $0 |
| 2019-08 | 180,000 | $571,200 | 0 | $0 | 0 | $0 |
| 2019-01 | 0 | $0 | 0 | $0 | 15,000 | $26,400 |
| 2018-07 | 0 | $0 | 0 | $0 | 35,000 | $69,475 |
| 2018-04 | 0 | $0 | 0 | $0 | 26,978 | $23,740 |
| 2018-03 | 6,172,837 | $19,845,670 | 0 | $0 | 0 | $0 |
| 2017-12 | 1,519,096 | $15,190 | 0 | $0 | 0 | $0 |
| 2017-10 | 300,000 | $561,000 | 0 | $0 | 0 | $0 |
| 2017-09 | 522,829 | $783,325 | 0 | $0 | 0 | $0 |
| 2016-10 | 3,660,667 | $2,245,099 | 0 | $0 | 0 | $0 |
| 2016-07 | 1,145,258 | $11,452 | 0 | $0 | 0 | $0 |
| 2016-06 | 3,753,855 | $4,467,087 | 0 | $0 | 0 | $0 |
| 2016-02 | 1,688,877 | $16,888 | 0 | $0 | 0 | $0 |
| 2016-01 | 46,800 | $34,081 | 0 | $0 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2022-09-08 | Huang James (Director) | Buy | 33,300 | 4.28 | 142,623 |
| 2022-09-07 | Huang James (Director) | Buy | 3,111 | 4.00 | 12,434 |
| 2022-09-06 | Huang James (Director) | Buy | 19,162 | 3.89 | 74,597 |
| 2022-09-02 | Huang James (Director) | Buy | 400 | 3.74 | 1,496 |
| 2022-09-01 | Huang James (Director) | Buy | 11,821 | 3.72 | 44,009 |
| 2022-08-31 | Huang James (Director) | Buy | 24,975 | 3.75 | 93,531 |
| 2022-08-26 | Huang James (Director) | Buy | 39,527 | 3.75 | 148,186 |
| 2022-08-24 | Huang James (Director) | Buy | 5,000 | 3.75 | 18,750 |
| 2022-08-23 | Huang James (Director) | Buy | 40,000 | 3.50 | 140,000 |
| 2022-08-22 | Huang James (Director) | Buy | 23,105 | 3.46 | 80,035 |
| 2022-08-19 | Huang James (Director) | Buy | 171,116 | 3.27 | 559,378 |
| 2021-11-18 | He Wei-wu (Chairman and CEO) | Buy | 200,000 | .98 | 196,000 |
| 2021-11-17 | He Wei-wu (Chairman and CEO) | Buy | 200,000 | .99 | 198,000 |
| 2021-08-19 | He Wei-wu (Chairman and CEO) | Buy | 180,000 | 1.26 | 226,800 |
| 2021-08-18 | He Wei-wu (Chairman and CEO) | Buy | 300,000 | 1.29 | 387,000 |
| 2021-03-26 | He Wei-wu (Chairman and CEO) | Buy | 3,000,000 | 2.05 | 6,149,999 |
| 2020-12-17 | Xu Weihao (Chief Financial Officer) | Buy | 4,000 | 2.63 | 10,540 |
| 2020-12-16 | Xu Weihao (Chief Financial Officer) | Buy | 2,000 | 2.44 | 4,880 |
| 2020-11-23 | He Wei-wu (Chairman and CEO) | Buy | 100,000 | 2.18 | 218,000 |
| 2020-11-20 | He Wei-wu (Chairman and CEO) | Buy | 127,471 | 2.12 | 270,238 |
| 2020-07-22 | Zhang Larry (President) | Buy | 20,153 | 1.90 | 38,290 |
| 2020-07-22 | He Wei-wu (Chairman and CEO) | Buy | 4,152,426 | 1.90 | 7,889,609 |
| 2020-05-20 | He Wei-wu (Chairman and CEO) | Buy | 56,464 | 2.37 | 133,819 |
| 2020-05-19 | He Wei-wu (Chairman and CEO) | Buy | 29,801 | 2.03 | 60,496 |
| 2020-05-18 | He Wei-wu (Chairman and CEO) | Buy | 338,932 | 2.02 | 684,642 |
| 2020-05-15 | He Wei-wu (Chairman and CEO) | Buy | 100,000 | 1.82 | 182,000 |
| 2020-03-27 | He Wei-wu (Chairman and CEO) | Buy | 6,880 | 2.08 | 14,310 |
| 2020-03-26 | He Wei-wu (Chairman and CEO) | Buy | 328,095 | 2.09 | 685,718 |
| 2020-03-25 | He Wei-wu (Chairman and CEO) | Buy | 196,398 | 1.94 | 381,012 |
| 2020-03-19 | He Wei-wu (Chairman and CEO) | Buy | 234,488 | 1.57 | 368,146 |
| 2020-03-18 | He Wei-wu (Chairman and CEO) | Buy | 501,322 | 1.52 | 762,009 |
| 2020-03-17 | He Wei-wu (Chairman and CEO) | Buy | 264,192 | 1.50 | 396,288 |
| 2019-08-16 | He Wei-wu (Chief Executive Officer) | Buy | 20,000 | 3.20 | 64,000 |
| 2019-08-14 | He Wei-wu (Chief Executive Officer) | Buy | 160,000 | 3.17 | 507,200 |
| 2019-01-14 | Hu Cynthia W. (COO, Gen Counsel & Secretary) | Option Ex | 15,000 | 1.76 | 26,400 |
| 2018-07-12 | Capitelli Sara B (VP Fin & Principal Account Officer) | Option Ex | 35,000 | 1.99 | 69,475 |
| 2018-04-12 | Capitelli Sara B (VP Fin & Principal Account Officer) | Option Ex | 26,978 | .88 | 23,740 |
| 2018-03-21 | Zhou Quan | Buy | 3,086,418 | 3.19 | 9,845,673 |
| 2018-03-19 | He Wei-wu | Buy | 3,086,419 | 3.24 | 9,999,997 |
| 2017-12-22 | Spectrum Pharmaceuticals Cayman, L.p. (10% Owner) | Buy | 1,519,096 | .01 | 15,190 |
| 2017-10-10 | He Wei-wu | Buy | 100,000 | 1.95 | 195,000 |
| 2017-10-06 | He Wei-wu | Buy | 100,000 | 1.86 | 186,000 |
| 2017-10-05 | He Wei-wu | Buy | 100,000 | 1.80 | 180,000 |
| 2017-09-19 | He Wei-wu | Buy | 34,002 | 1.78 | 60,523 |
| 2017-09-18 | He Wei-wu | Buy | 173,500 | 1.75 | 303,625 |
| 2017-09-15 | He Wei-wu | Buy | 127,702 | 1.49 | 190,275 |
| 2017-09-14 | He Wei-wu | Buy | 187,625 | 1.22 | 228,902 |
| 2016-10-28 | Spectrum Pharmaceuticals Cayman, L.p. (10% Owner) | Buy | 1,789,062 | .01 | 17,890 |
| 2016-10-03 | He Wei-wu | Buy | 1,871,605 | 1.19 | 2,227,209 |
| 2016-07-20 | Spectrum Pharmaceuticals Cayman, L.p. (10% Owner) | Buy | 164,526 | .01 | 1,645 |
| 2016-07-14 | Spectrum Pharmaceuticals Cayman, L.p. (10% Owner) | Buy | 980,732 | .01 | 9,807 |
| 2016-06-24 | Shong Hugo | Buy | 3,753,855 | 1.19 | 4,467,087 |
| 2016-02-22 | Spectrum Pharmaceuticals Cayman, L.p. (10% Owner) | Buy | 1,688,877 | .01 | 16,888 |
| 2016-01-19 | Ren Ken Keyong (CEO and Director) | Buy | 15,000 | .72 | 10,875 |
| 2016-01-19 | Ren Ken (CEO and Director) | Buy | 15,000 | .72 | 10,875 |
| 2016-01-19 | Hu Cynthia W. (COO) | Buy | 16,800 | .73 | 12,331 |
Insider trading activities including stock purchases, stock sales, and option exercises of ENMD listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Casi Pharmaceuticals, Inc. (symbol ENMD, CIK number 895051) see the Securities and Exchange Commission (SEC) website.